相关实验视频

Updated: Jan 9, 2026

Combined Invasive Subcortical and Non-invasive Surface Neurophysiological Recordings for the Assessment of Cognitive and Emotional Functions in Humans

Combined Invasive Subcortical and Non-invasive Surface Neurophysiological Recordings for the Assessment of Cognitive and Emotional Functions in Humans

Published on: May 19, 2016

在阿尔茨海默病中探索阿尔法脱同步,使用连贯性分析

Chun-Wei Lin, Hsiao-Wen Chung, Wen-Chau Wu

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference

|December 3, 2025

概括

电脑电图 (EEG) 可能有助于诊断阿尔茨海默病 (AD). 患有阿尔茨海默氏症的患者表现出降低的α脱同步,表明大脑连接的改变,这可能是早期诊断生物标志物.

科学领域:

神经科学是一个神经科学.
医疗成像医学成像
生物标志物生物标志物

背景情况:

阿尔茨海默病 (AD) 是一种常见的痴呆症,没有治疗方法,需要早期诊断进行干预.
脑电图 (EEG) 测量大脑活动,并显示了早期AD检测的潜力.
以前的研究将EEG中的α频段能量降低与状态转换期间同步性降低联系起来.

研究的目的:

通过使用EEG来研究阿尔茨海默病中的α脱同步.
探索EEGα频段连贯性的实用性,作为AD中的功能连接的指数.
为了比较AD患者和健康对照者之间的α脱同步模式.

主要方法:

使用脑电图 (EEG) 记录大脑活动.
在眼睛开放和闭眼条件下分析了α频段能量和连贯性.
在一组阿尔茨海默病患者和一个正常的对照组之间比较了EEG指标.

主要成果:

与对照组相比,阿尔茨海默病组表现出较低的α波段能量.
在AD组中观察到阿尔法频段连贯性减少,这表明功能连接性受损.
减少α脱同步是阿尔茨海默病患者的一个关键发现.

结论:

阿尔茨海默病与显著减少的α脱同步有关.
脑电图α频段的连贯性和能量变化可能反映了与AD病理相关的功能连接性变化.
减弱的α脱同步是早期诊断阿尔茨海默病的潜在生物标志物.

更多相关视频

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

Microstate and Omega Complexity Analyses of the Resting-state Electroencephalography

Microstate and Omega Complexity Analyses of the Resting-state Electroencephalography

Published on: June 15, 2018

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...